Showing results (151-160 of 161) with videos related to
Sort By:
Pageof 17
Science (New York, N.Y.)|December 12, 1986
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelopeS D Putney, T J Matthews, W G Robey, et al.The American Journal of Medicine|July 1, 1988
Human T-cell lymphotropic virus I and adult T-cell leukemia: report of a cluster in North CarolinaJ B Weinberg, R A Spiegel, D L Blazey, et al.Vaccine|March 10, 1998
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M J McElrath, T J Matthews, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1990
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodiesD S Tyler, S D Stanley, S Zolla-Pazner, et al.AIDS Research and Human Retroviruses|February 24, 1999
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, L Corey, G B Patel, et al.AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.Pageof 17